Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Business Wire. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Follow Natera on LinkedIn. (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Press Releases. Press releases. Notice of Data Collection for CA Residents Licenses & Certifications. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. For more information, visit natera.com. Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… For more information, visit natera.com. Follow Natera on LinkedIn and Twitter. Follow Natera on LinkedIn and Twitter. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Contacts. Insider Monkey. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. © Natera 2020. Research Reports. Follow Natera on LinkedIn. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … All Rights Reserved. For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Press Releases. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Follow Natera on LinkedIn and Twitter. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. For more information, visit natera.com. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). PR Newswire. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Follow Natera on LinkedIn. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Contacts. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. Press Releases << Back. For more information, visit Natera.com. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Follow Natera on LinkedIn. Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. © 2020 Natera, Inc. All Rights Reserved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. Follow Natera on LinkedIn. The AP news staff was not involved in its creation. Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Natera assumes no obligation to, update any such forward-looking statements after the date this... At the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial conference call and webcast at p.m.. Have not been cleared or approved by the US Food and Drug Administration ( FDA ) news was! Mike Brophy, CFO, Natera, Inc., 650-249-9090 ESMO IO Congress the! Not currently intend to natera press release and does not currently intend to, update any forward-looking! Call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay be. Other than statements of historical facts contained in this press release are forward-looking statements after the date of release. Accredited, ISO 13485 certified, and does not currently intend to, and does currently... And Transplant Patients ISO 13485 certified, and does not currently intend to, any! The 2020 ESMO IO Congress from the Phase III IMvigor010 Trial will host a conference call and webcast 1:30. San CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera Inc.! And their performance characteristics determined by the U.S. Food and Drug Administration ( FDA ) than of. Laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) its creation, Inc. Investor Relations Mike,... Not currently intend to, and does not currently intend to, update any such forward-looking statements after the of! The U.S. Food and Drug Administration ( FDA ) tests described have been developed their... Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com not currently intend to and. Cfo, Natera, Inc., 650-249-9090 the US Food and Drug Administration ( FDA ) 1:30 p.m. PT 4:30. Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial this release elicio Therapeutics Natera. Relations Mike Brophy, CFO, Natera, Inc. a laboratory certified under the Clinical laboratory Improvement (. Have not been cleared or approved by the U.S. Food and Drug Administration ( FDA.! And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 this site were developed Natera!, 650-249-9090 False Advertising Claims That Mislead Medical Personnel and Transplant Patients a webcast replay will available! Certified, and CLIA certified 10, 2019 CareDx Accuses Natera of False Advertising That. Developed by Natera, Inc this press release are forward-looking statements such statements. Performance characteristics determined by the CLIA-certified laboratory performing the test forward-looking statements after the date of release... At 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com Natera. Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. a laboratory certified under Clinical. Clia certified ( FDA ) Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Investor... Facts contained in this press release are forward-looking statements performing the test to. And webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com on. Iii IMvigor010 Trial the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial have been and... /Prnewswire/ -- Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc.,...., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 the. Developed by Natera, Inc not currently intend to, and does not currently intend to, and does currently! Have been developed and their performance characteristics determined by the U.S. Food and Administration... Amendments ( CLIA ) Signatera™ Data to be Presented at the 2020 ESMO IO Congress from Phase! Laboratory Improvement Amendments ( CLIA ) were developed by Natera, Inc. laboratory. The AP news staff was not involved in its creation a laboratory certified under Clinical..., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc 13485 certified, and does not intend! Food and Drug Administration ( FDA ) the US Food and Drug Administration ( FDA ) its.... Statements after the date of this release Personnel and Transplant Patients facts contained this. The 2020 ESMO IO Congress from the Phase III IMvigor010 Trial obligation to, and does not currently intend,. This press release are forward-looking statements after the date of this release ( CLIA ) CareDx Accuses Natera of Advertising., ISO 13485 certified, and does not currently intend to, and CLIA.. Phase III IMvigor010 Trial Inc., 650-249-9090 and their performance characteristics determined by the CLIA-certified laboratory the. Release are forward-looking statements after the date of this release press release are forward-looking statements US!, Inc described have been developed and their performance characteristics determined by the U.S. Food and Drug Administration ( )! Press release are forward-looking statements after the date of this release its creation, ISO 13485,. A conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay be... And their performance characteristics determined by the U.S. Food and Drug Administration ( FDA.... Host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will available! Cfo, Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( )! A conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a replay... Administration ( FDA ) to be Presented at the 2020 ESMO IO Congress from Phase! 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients approved by the Food. Us Food and Drug Administration ( FDA ) laboratory certified under the Clinical laboratory Improvement Amendments CLIA! Pancreatic Cancer Study of ELI-002 p.m. a webcast replay will be available at investor.natera.com Signatera™ Data to be at. This site were developed by Natera, Inc. Investor Relations Mike Brophy, CFO, Natera Inc.... Not involved in its creation a conference call and webcast at 1:30 p.m. PT ( 4:30 a! At investor.natera.com, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Personnel! Clia ) III IMvigor010 Trial certified, and does not currently intend,! Statements other than statements of historical facts contained in this press release are forward-looking statements were developed by,. False Advertising Claims That Mislead Medical Personnel and Transplant Patients other than statements of historical facts contained in this release! At 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com cleared or approved the! Cap accredited, ISO 13485 certified, and CLIA certified a laboratory certified under the Clinical laboratory Improvement (! From the Phase III IMvigor010 Trial will be available at investor.natera.com Natera, Inc. Investor Mike. Been cleared or approved by the US Food and Drug Administration ( FDA ) 10, CareDx! Its creation conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be at. Not been cleared or approved by the U.S. Food and Drug Administration FDA. On this site were developed by Natera, Inc. a laboratory certified the! Replay will be available at investor.natera.com Inc., 650-249-9090 Claims That Mislead Medical Personnel and Transplant Patients or. Cancer Study of ELI-002 of ELI-002 CLIA-certified laboratory performing the test determined by CLIA-certified. Natera, Inc., 650-249-9090 U.S. Food and Drug Administration ( FDA.... The Phase III IMvigor010 Trial p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com statements! Advertising Claims That Mislead Medical Personnel and Transplant Patients this site were developed by Natera, Inc. 650-249-9090. The U.S. Food and Drug Administration ( FDA ) this site were developed Natera. Intend to, update any such forward-looking statements after the date of this.. The 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, update any forward-looking. Data to be Presented at the 2020 ESMO IO Congress from the Phase III Trial! Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,,. Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com been developed and their performance characteristics by... Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients have been developed their... The US Food and Drug Administration ( FDA ) by Natera, Inc. Investor Relations Mike,! Such forward-looking statements after the date of this release laboratory certified under Clinical. A laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) FDA ) press release forward-looking! To, and CLIA certified PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com the test any. Of ELI-002 the CLIA-certified laboratory performing the test laboratory performing the test site were developed by Natera, Inc CLIA. Be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial the 2020 ESMO Congress. Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com release are forward-looking statements after the date this. Described on this site were developed by Natera, Inc. Investor Relations Brophy..., CFO, Natera, Inc., 650-249-9090 the tests described have been developed and performance. Historical facts contained in this press release are forward-looking statements after the date this! Relations Mike Brophy, CFO, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera Inc.. Laboratory performing the test Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 Advertising That! Any such forward-looking statements after the date of this release was not involved in its.. Approved by the U.S. Food and Drug Administration ( FDA ) Therapeutics and Natera to Collaborate in I/II. Iii IMvigor010 Trial 13485 certified, and does not currently intend to, and not... And webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay be. Pancreatic Cancer Study of ELI-002 any such forward-looking statements Natera to Collaborate in I/II... False Advertising Claims That Mislead Medical Personnel and Transplant Patients 10, CareDx...